Claims for Patent: 9,889,102

Summary for Patent: 9,889,102

Title:	Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
Abstract:	The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention may modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.
Inventor(s):	Kim; Felix J. (Philadelphia, PA), Salvino; Joseph M. (Chester Springs, PA)
Assignee:	Drexel University (Philadelphia, PA)
Application Number:	15/176,812
Patent Claims:	1. A compound of Formula (II): R.sup.A--R.sup.B (II), wherein: R.sup.A is selected from the group consisting of ##STR00032## X.sup.4 is selected from the group consisting of --OCH.sub.3, F, Cl, Br, and I; and R.sup.B is selected from the group consisting of: ##STR00033## ##STR00034## or a salt, solvate, or N-oxide thereof; and any combinations thereof. 2. A pharmaceutical composition comprising at least one compound of claim 1, or a salt, solvate, or N-oxide thereof, and a pharmaceutically acceptable carrier. 3. The composition of claim 1, further comprising at least one additional therapeutic agent that inhibits the ubiquitin proteasome system (UPS) or autophagic survival pathway. 4. The composition of claim 3, wherein the therapeutic agent is selected from the group consisting of growth factor receptor inhibitors, monoclonal antibodies against growth factor receptors, hormone receptor antagonists, autophagy modulators, ER stress response inhibitors, proteasome inhibitors, p97/VCP inhibitors and any combinations thereof. 5. The composition of claim 4, wherein the therapeutic agent is selected from the group consisting of somatostatin; lanreotide; angiopeptin; dermopeptin; octreotide; pegvisomant; 3-methyladenine; chloroquine; hydroxychloroquine; wortmannin; eeyarestatin I; salubrinal; versipelostatin; danoprevir; adamantane-acetyl-(6-aminohexanoyl)3-(leucinyl)3-vinyl-(methyl)-sulfone; N-acetyl-L-leucyl-L-leucyl-L-methional; N[(phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-L-leu- cinamide; (2R,3S,4R)-3-hydroxy-2-[(1S)-1-hydroxy-2-methyl propyl]-4-methyl-5-oxo-2-pyrrolidinecarboxy-N-acetyl-L-cysteine thioester; N--[N--(N-acetyl-L-leucyl)-L-leucyl]-L-norleucine; lactacystin; 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride; (S)-1-carboxy-2-phenyl]-carbamoyl-arg-val-arginal; bovine pancreatic trypsin inhibitor; [(2S,2R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-leucine; N--[(S)-1-carboxy-isopentyl)-carbamoyl-alpha-(2-iminohexahydro-4-(S)-pyri- midyl]-L-glycyl-L-phenylalaninal; ethylenediamine-tetraacetic acid disodium salt dihydrate; acetyl-leucyl-leucyl-arginal; isovaleryl-val-val-AHMHA-ala-AHMHA where AHMHA=(3S,4S)-4-amino-3-hydroxy-6-methylheptanoic acid; N-alpha-L-rhamnopyranosyloxy (hydroxyphosphinyl)-L-leucyl-L-tryptophan; phenylmethanesulfonyl fluoride; bortezomib; carfilzomib; ONX 0912; NPI-0052; CEP-18770; MLN9708; disulfiram; epigallocatechin-3-gallate; salinosporamide A; PI3K inhibitors; lapatinib; rapamycin; rapalogs; HSP inhibitors; androgen receptor inhibitors; a salt thereof, and any combinations thereof. 6. The composition of claim 2, which is formulated for at least one selected from the group consisting of sustained release formulation, delayed release formulation, and pulsatile release formulation. 7. The composition of claim 2, which is formulated for at least one administration route selected from the group consisting of oral, parenteral, transdermal, transmucosal, intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical. 8. A method of treating in a subject a disease or disorder selected from the group consisting of breast cancer and prostate cancer, the method comprising administering to the subject a therapeutically effective amount of at least one compound of claim 1, or a salt, solvate or N-oxide thereof. 9. The method of claim 8, wherein the cancer is breast cancer. 10. The method of claim 8, wherein the cancer is prostate cancer. 11. The method of claim 10, wherein the prostate cancer is castrate-sensitive or castrate-insensitive prostate cancer. 12. The method of claim 8, wherein the at least one compound is administered to the subject as part of a pharmaceutically acceptable composition. 13. The method of claim 12, wherein the pharmaceutically acceptable composition is formulated for at least one selected from the group consisting of sustained release formulation, delayed release formulation, and pulsatile release formulation. 14. The method of claim 8, wherein the subject is a mammal. 15. The method of claim 14, wherein the mammal is a human. 16. The method of claim 14, wherein the compound is administered to the subject by at least one administration route selected from the group consisting of oral, parenteral, transdermal, transmucosal, intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical. 17. The pharmaceutical composition of claim 2, wherein the composition is a cream or lotion. 18. The pharmaceutical composition of claim 17, wherein the compound is selected from the group consisting of 1-(3-(4-fluorophenoxy)propyl)-3-(4-iodophenyl)guanidine (Compound A); 1-(3-(4-fluorophenoxy)propyl)-3-(4-methoxyphenyl)guanidine (Compound B); 1-(3-(4-fluorophenoxy)propyl)-3-(4-chlorophenyl)guanidine (Compound (G); or a salt, solvate or N-oxide thereof, and any combinations thereof. 19. A transdermal patch comprising at least one compound of claim 1, or a salt, solvate or N-oxide thereof, and any combinations thereof. 20. The transdermal patch of claim 19, wherein the compound is selected from the group consisting of 1-(3-(4-fluorophenoxy)propyl)-3-(4-iodophenyl)guanidine (Compound A); 1-(3-(4-fluorophenoxy)propyl)-3-(4-methoxyphenyl)guanidine (Compound B); 1-(3-(4-fluorophenoxy)propyl)-3-(4-chlorophenyl)guanidine (Compound G); or a salt, solvate or N-oxide thereof, and any combinations thereof. 21. The compound of claim 1, wherein R.sup.A is ##STR00035## 22. The compound of claim 1, wherein R.sup.A is ##STR00036## 23. The compound of claim 22, wherein X.sup.4 is selected from the group consisting of F, Cl, Br, and I. 24. The compound of claim 22, wherein X.sup.4 is OCH.sub.3. 25. The compound of claim 1, wherein R.sup.A is ##STR00037##

Details for Patent 9,889,102

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	03/25/2003		2032-07-19
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	07/31/2014		2032-07-19